Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan plus budigalimab vs standard of care in first-line non-squamous NSCLC without actionable alterations
jRCT2031250030Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in non-small cell lung cancer (NSCLC) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-limiting toxicities of telisotuzumab adizutecan (Part 1), Objective response by BICR (Part 2) and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250030.